BioLineRx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2009
Net Income	-49.15	-60.61	-24.95	-27.05	-30.02	-25.45	Upgrade
Depreciation & Amortization	2.02	1.38	0.65	0.7	0.93	0.94	Upgrade
Share-Based Compensation	2.42	2.32	2.25	1.5	1.27	1.76	Upgrade
Other Operating Activities	16.01	34.3	-4.19	1.28	4.61	0.08	Upgrade
Operating Cash Flow	-28.7	-22.61	-26.24	-23.57	-23.21	-22.67	Upgrade
Capital Expenditures	-0.12	-0.12	-0.13	-0.1	0	-0.07	Upgrade
Change in Investments	11.69	1.74	4.32	-38.13	16.67	5.33	Upgrade
Other Investing Activities	-0.08	-0.18	-0.19	-	-	-0.01	Upgrade
Investing Cash Flow	11.49	1.44	4.01	-38.22	16.67	5.26	Upgrade
Share Issuance / Repurchase	-	14.12	14.36	50.41	19.25	20.3	Upgrade
Debt Issued / Paid	-2.83	-1.99	6.07	-3.57	-3.36	-1.1	Upgrade
Other Financing Activities	17.04	2.93	-	10.91	1.97	-	Upgrade
Financing Cash Flow	14.21	15.06	20.44	57.75	17.87	19.19	Upgrade
Exchange Rate Effect	-0.08	-0.22	-0.61	0.21	0.21	0.11	Upgrade
Net Cash Flow	-3	-6.11	-1.8	-4.05	11.33	1.79	Upgrade
Free Cash Flow	-28.82	-22.72	-26.37	-23.67	-23.21	-22.73	Upgrade
Free Cash Flow Margin	-247.25%	-473.42%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.40	-0.35	-0.51	-0.54	-1.38	-2.33	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).